文献速递前列腺增生与排尿功能障碍

美国钬激光前列腺剜除术的采用与结局

Adoption and Outcomes of Holmium Laser Enucleation of the Prostate in the United States.
PubMed 文献 · Urology · 2023-06-14

研究利用Premier医疗数据库2000至2019年218793例因良性前列腺增生接受内镜手术的男性,比较钬激光前列腺剜除术(HoLEP)与其他内镜术式的采用趋势及结局。HoLEP占全部手术的3.2%,从2008年1.1%增至2019年4%;HoLEP较经尿道前列腺电切术(TURP)90天再入院几率更低(OR 0.87,p=0.025),再治疗几率与TURP相近,而光选择性前列腺汽化术和前列腺尿道提升术2年内再治疗几率更高。

要点

  • HoLEP占2000至2019年良性前列腺增生内镜手术的3.2%,从2008年1.1%增至2019年4%。
  • HoLEP较TURP的90天再入院几率更低(OR 0.87,p=0.025)。
  • HoLEP的1年(OR 0.96,p=0.7)和2年(OR 0.98,p=0.9)再治疗几率与TURP相近。

核心结论

  • HoLEP是治疗良性前列腺增生的安全疗法,较金标准TURP再入院率更低、再治疗率相当。
  • 尽管HoLEP安全有效,其采用率仍落后于其他内镜手术且保持在较低水平。

研究设计与样本

  • 利用Premier医疗数据库识别2000至2019年因良性前列腺增生接受内镜治疗的男性,共218793例。
  • 比较各术式的相对比例和年度医生手术量数据以识别采用与使用趋势。
  • 评估术后30天和90天再入院率及再治疗率,并采用多因素逻辑回归分析术式与结局的关联。

主要发现

  • HoLEP占2000至2019年全部良性前列腺增生手术的3.2%(n=6967),从2008年的1.1%增至2019年的4%。
  • HoLEP患者90天再入院几率低于TURP(OR 0.87,p=0.025)。
  • HoLEP与TURP的1年再治疗几率(OR 0.96,p=0.7)和2年再治疗几率(OR 0.98,p=0.9)相近。
  • 光选择性前列腺汽化术和前列腺尿道提升术患者2年内再治疗几率更高(OR 1.20,P<0.001;OR 1.87,P<0.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the utilization of holmium laser enucleation of the prostate (HoLEP) using a large real-world cohort. We compare the safety, readmission, and retreatment rates of HoLEP to other widely used endoscopic surgical interventions for benign prostatic hyperplasia (BPH) including transurethral resection of the prostate (TURP), photoselective vaporization of the prostate, and prostatic urethral lift. METHODS: Men who underwent endoscopic treatments for BPH from 2000 to 2019 were identified in the Premier Healthcare Database (n = 218,793). We compared the relative proportion of each procedure performed and annual physician volume data to identify trends in adoption and utilization. Readmission and retreatment rates were determined at both 30- and 90-days postoperation. Multivariable logistic regression was used to assess the association between procedure type and outcomes. RESULTS: HoLEP accounted for 3.2% (n = 6967) of all the BPH procedures performed between 2000 and 2019 and increased from 1.1% of the procedures in 2008 to 4% in 2019. Patients undergoing HoLEP had lower odds of 90-days readmission compared to TURP (Odds ratio (OR) 0.87, p = 0.025). HoLEP had similar odds of retreatment compared to TURP at both 1-year (OR 0.96, p = 0.7) and 2-years (OR 0.98, p = 0.9), while patients undergoing photoselective vaporization of the prostate and prostatic urethral lift were more likely to retreat within 2-years (OR 1.20, P < 0.001; OR 1.87, P < 0.001). CONCLUSION: HoLEP is a safe therapy for BPH with lower readmission and comparable retreatment rates to the gold standard TURP. Despite this, the utilization of HoLEP has lagged behind other endoscopic procedures and remains low.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Weinstein IC, Wu X, Arenas-Gallo C, et al. Adoption and Outcomes of Holmium Laser Enucleation of the Prostate in the United States. Urology. 2023. PMID: 37328009. doi:10.1016/j.urology.2023.05.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。